StemLink Corporation, the Japanese subsidiary of Stemcell Holdings, Inc., has invested in a cell culture and processing facility constructed in Amagasaki City, Hyogo Prefecture.
The action has been made by RMDC Corporation, that is a subsidiary of PATH Corporation. This is a venture company listed on the Standard market of the Tokyo Stock Exchange (TSE).
The cell culture and processing facility is scheduled for completion in July 2024.
PATH Corporation [TSE:3840] has a singular advantage due to its innovative business development and diverse business models. Particularly noteworthy are its mail order business in the cosmetics and beauty, health fields and its business consulting services utilizing blockchain technology.
Information
Related News Release by PATH Corporation